Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Merck, J&J's New Hepatitis C Treatments Fetch $31,000 in France

April 5, 2011

Though they are still under review by the European Medicines Agency, two new hepatitis C virus (HCV) treatments are already being prescribed to French patients. In December, telaprevir and boceprevir received special temporary authorization in a program for critically ill patients for whom no other effective treatment is available, said French pharmaceutical regulator AFSSAPS.

Advertisement

Used as a complement to existing HCV treatment, telaprevir, made by U.S.-based Johnson & Johnson and Vertex Pharmaceuticals Inc., and boceprevir, by Merck & Co., boost cure rates from roughly half of patients to between two-thirds and three-quarters, studies show. Both drugs are protease inhibitors made using the same technologies that led to improved HIV drugs. Approximately 500 patients currently are being treated in France, said Michel Bonjour, spokesperson for SOS Hepatites.

But under the program, telaprevir costs €22,000 (US $31,290) and boceprevir €30,000 (US $42,670). France's national health insurance program covers the entire cost. While Merck and J&J executives said the price may come down once the drugs are approved for the broader market, doctors worry high pricing could affect treatment access.

England, Russia and countries in Eastern Europe are likely to delay use or restrict access to the drugs if their prices remain high, said Antonio Craxi, director of gastroenterology and internal medicine at the University of Palermo. Italy and Spain could do the same, he said. Existing HCV treatments cost Italy €350 million annually (US $498 million). "If you triple the cost, that would be more than €1 billion [US $1.42 billion]," he noted.

Howard Liang, a Boston-based analyst with Leerink Swann & Co., estimates that the drugs will be priced at $35,000 to $40,000 in the United States.

Back to other news for April 2011

Adapted from:
Bloomberg News
04.03.2011; Naomi Kresge; Carol Matlack


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement